

CD47 | SIRPα

SUMMIT

Targeting The Leading "Don't Eat Me" Signal

November 4 - 5, 2020 | EST Timezone

Networking Available All Day

9:00am - 5:30pm: Day 1 - Wednesday, November 4th

9:00am - 1:00pm: Day 2 - Thursday, November 5th

As the main agenda progresses throughout the day, you will have the choice of listening in to / participating in the live content or spend more of your time networking with your peers.

Here is how you will be able to achieve this, outside of the networking sessions on the agenda

- **See who's in the room** - you will be able to message all live attendees and connect with those who respond.
- **Schedule 1-2-1 video calls** with your connections at any time that suits you.
- **Open Networking** - think of this as the event lobby where you can replicate those all-important "water-cooler" moments.

You will be able to hop seamlessly between networking and on-going agenda sessions at any point.

With networking available all day, this will provide you with even more opportunities to meet your potential future partners and collaborators.

Conference Day 1: Wednesday, November 4th 2020

8:00am Conference Platform Opens

The conference platform opens before the agenda starts, giving you time to plug the presentations, panels and discussions into your agenda for the rest of the day. This also gives you plenty of time to get familiar with the platform.

Location: **Stage**

9:00am Chair's Opening Remarks & Setting the Scene

- A look at the day ahead - what will be the key takeaways we should achieve by the end of this summit?
- How far have we come in the CD47|SIRP α space since last April?

Kipp Weiskopf, Whitehead Fellow, [Whitehead Institute](#)

9:05am Keynote Presentation: Fundamental Biology of the CD47|SIRP α Checkpoint

Timo Van Den Berg, Professor of Immunotherapy, Head Department of Blood Cell Research, [Sanquin Research, Amsterdam University Medical Center](#)

9:25am Wellness Break

Get-up and have a stretch before the next session begins.

9:30am Presentation: **What Do We Know About the Fundamental Biology Behind Alternative SIRP Homologs and an Overview of OSE Immunotherapeutics' Approach**

Nicolas Poirier, CSO, [OSE Immunotherapeutics](#)

9:50am Wellness Break

Get-up and have a stretch before the next session begins.

Location: **Sessions**

10:00am Panel Discussion: **What Impact is our Current Level of Understanding of the CD47|SIRP α Checkpoint Having on the Industry?**

- What knowledge do we need to further the development of CD47|SIRP α targeted therapies?
- What are the specific hurdles within research that prevents information about the CD47|SIRP α being discovered?
- Do we understand sufficiently which immune functions are controlled by CD47-SIRP α and how?
- As we move further into human trials, what are we expecting to learn about the fundamental biology of CD47/SIRPa?

Dan Pereira, CSO, [Arch Oncology](#)

Michal Caspi Tal, Instructor & Team Lead, [Stanford University](#)

Anthony Schwartz, CEO, [Morphiex](#)

Timo Van Den Berg, Professor of Immunotherapy, Head Department of Blood Cell Research, [Sanquin Research](#), [Amsterdam University Medical Center](#)

10:25am-10:45am **Open Q&A with Speakers**

This is your chance to pose your burning questions to the expert speakers from the previous panel.

Dan Pereira, CSO, [Arch Oncology](#)

Michal Caspi Tal, Instructor & Team Lead, [Stanford University](#)

Anthony Schwartz, CEO, [Morphiex](#)

Timo Van Den Berg, Professor of Immunotherapy, Head Department of Blood Cell Research, [Sanquin Research](#), [Amsterdam University Medical Center](#)

Actively or passively take part in this session.

Location: **Networking**

10:45am **Speed Networking**

In the purpose-built Networking area, get ready to expand your network through randomly assigned 1 on 1 quick-fire video meetings. You can choose who you want to “connect” with and then set-up 1-2-1 in-depth catch-up’s throughout the rest of the event.

This function also ensures that you don’t meet the same person more than once, allowing you to meet as many fellow attendees as you desire.

Your future collaborators or partners could be just one click away!

Location: **Stage**

11:15am Presentation: **A Novel MOA-reflective Bioassay for Quantifying Potency of Therapeutics Targeting the SIRP α | CD47 Signaling Axis**

- Assay principle and relevance to MOA of SIRP α /CD47 signaling in macrophages
- Assay characterization and optimization/development history
- Suitability of the assay for potency determination and characterization of anti-SIRP α /anti-CD47
- Therapeutics

Jane Lamerdin, Director, R&D, **Eurofins DiscoverX**

11:40am Wellness Break

Get-up and have a stretch before the next session begins.

11:45am Presentation: **How Do Macrophages Work In Relation To CD47 | SIRP α ?**

- We learn more about the fundamental biology behind macrophages and how they interact with CD47.
- Why Macrophages rather than dendritic/myeloid cells?
- What is the role of macrophage polarity as it pertains to promoting phagocytosis following SIRPa/CD47 blockade?

Stephanie Dougan, Assistant Professor, [Dana-Farber Cancer Institute](#)

12:05pm Wellness Break

Get-up and have a stretch before the next session begins.

Location: **Sessions**

12:10pm Panel Discussion: **What Does “Eat Me” Mechanistically Mean for Macrophages In Relation To CD47 | SIRP α ?**

- How do we activate and how do we increase macrophage activity?
- What are the different types of macrophages, does the targeted therapy approach need to change depending on the type of macrophage?
- Can CD47/SIRPa blockade single-handedly influence what macrophages do with the tumor antigens after they are ‘eaten’?
- What other signals/pathways in macrophages need to be engaged?
- How do we measure/confirm macrophage phagocytosis in a clinical trial setting?

Siddhartha Mitra, Assistant Professor, [University of Colorado](#)

Sergio Trombetta, Senior Principal Scientist, Cancer Immunology & Immune Modulation, [Boehringer Ingelheim](#)

Stephanie Dougan, Assistant Professor, [Dana-Farber Cancer Institute](#)
Takashi Matozaki, Professor, Dean of the Graduate School of Medicine, [Kobe University](#)

12:35pm-12:50pm **Open Q&A with Speakers**

This is your chance to pose your burning questions to the expert speakers from the previous panel.

Siddhartha Mitra, Assistant Professor, [University of Colorado](#)
Sergio Trombetta, Senior Principal Scientist, Cancer Immunology & Immune Modulation, [Boehringer Ingelheim](#)
Stephanie Dougan, Assistant Professor, [Dana-Farber Cancer Institute](#)
Takashi Matozaki, Professor, Dean of the Graduate School of Medicine, [Kobe University](#)

Actively or passively take part in this session.

The CD47/SIRPa Summit includes an extended break in the middle to give you ample time for lunch and another chance to catch-up on the day job. Or if you have time, you can use this break for 1-2-1 meetings or open networking.

Location: **Stage**

2:00pm Presentation: **QPCTL - A Druggable Modifier of the CD47/SIRP Therapeutic Axis**

Sebastian Nijman, Founder & Managing Director, **Scenic Biotech**

2:20pm Wellness Break

Get-up and have a stretch before the next session begins.

2:25pm Presentation: **Tackling Solid Cancers using a Bispecific Antibody Approach - Light Chain Bioscience**

- A look at the advantages of targeting CD47 with a bispecific antibody approach.
- We hear about Mesothelin as a target for solid cancers.
- An insight into preclinical data for the CD47 x Mesothelin bispecific antibody.

Limin Shang, Pharmacology Director, **LightChain Bioscience**

2:45pm Wellness Break

Get-up and have a stretch before the next session begins.

Location: **Sessions**

2:50pm Panel Discussion: **Chemotherapy, T-cell Immunotherapy and Radiotherapy - Where do these Fit in Combination with CD47|SIRP α ?**

- What do we know so far about combining these targets with CD47|SIRP α both preclinically and clinically?
- How effectively does radiotherapy work alongside CD47|SIRP α ?
- What are the risks of combining these immuno-oncology targets?
- What are the potential impacts of immunogenic vs non-immunogenic cell killing on CD47|Sirpa compounds, does one route work better than the other?
- How predictive/how useful are preclinical models in this space?

Siddhartha Mitra, Assistant Professor, [University of Colorado](#)

André Veillette, Research Professor, [Montreal Clinical Research Institute \(IRCM\)](#)

Timothy Zheng, Executive Director, Immune Modulation, [Boehringer Ingelheim](#)

3:15pm-3:35pm **Open Q&A with Speakers**

This is your chance to pose your burning questions to the expert speakers from the previous panel.

Actively or passively take part in this session.

Siddhartha Mitra, Assistant Professor, [University of Colorado](#)

André Veillette, Research Professor, [Montreal Clinical Research Institute \(IRCM\)](#)

Timothy Zheng, Executive Director, Immune Modulation, **Boehringer Ingelheim**

Location: **Stage**

3:35pm Wellness Break

Get-up and have a stretch before the next session begins.

3:40pm Presentation: **ALX148: Designed For Safety To Maximize Efficacy**

- Design of ALX148 and mechanistic insights into its safety/efficacy profile
- Overview of clinical results from the ALX148 program

Jaume Pons, President & CEO, **ALX Oncology**

4:00pm Wellness Break

Get-up and have a stretch before the next session begins.

4:05pm Presentation: **Lemzoparlimab - A Differentiated CD47 Antibody in Clinical Development**

- An insight into how I-Mab Biopharma discovered an antibody with differentiated properties to reduce RBC binding.
- We learn about I-Mab Biopharma's attempt to understand the mechanisms underlying these differentiated properties.

Claire Xu, Head of US Site, **I-Mab Biopharma**

4:25pm Wellness Break

Get-up and have a stretch before the next session begins.

Location: **Sessions**

4:30pm Panel Discussion **What are the Predictive Biomarkers Arising when Targeting CD47|SIRP α Pathways?**

- What are the best biomarker strategies to validate how clinical trials are going?
- SIRP α /CD47 tumoral expression: is there any correlation with clinical efficacy?
- Macrophage/T-cell infiltrates: is there any correlation with clinical efficacy?
- What other biomarkers should be considered in regards to CD47|SIRP α drugs?
- What biomarkers are biotech companies using to track macrophages in clinic?

Moderated by: **André Veillette**, Research Professor, **Montreal Clinical Research Institute (IRCM)**

Claire Xu, Head of US Site, **I-Mab Biopharma**

Spencer Liang, Senior Director, Head of Immuno-Oncology, **Alector**

Limin Shang, Pharmacology Director, **LightChain Bioscience**

4:55pm - 5:15pm **Open Q&A with Speakers**

This is your chance to pose your burning questions to the expert speakers from the previous panel.

Actively or passively take part in this session.

André Veillette, Research Professor, **Montreal Clinical Research Institute (IRCM)**

Claire Xu, Head of US Site, **I-Mab Biopharma**

Spencer Liang, Senior Director, Head of Immuno-Oncology, **Alector**

Limin Shang, Pharmacology Director, **LightChain Bioscience**

Conference Day 2: Thursday, November 5th 2020

8:00am **Conference Platform Opens**

The conference platform opens before the agenda begins so that you can plug the presentations, panels and discussions into your calendar for the day ahead.

Location: **Stage**

9:00am **Chair's Opening Remarks**

- What have we learnt so far at CD47|SIRP α 2020?
- What can we expect from today?

Siddhartha Mitra, Assistant Professor, [University of Colorado](#)

9:05am Presentation: **An Insight into Trillium Therapeutics' Progress and What's To Come.**

Yaping Shou, Chief Medical Officer, [Trillium Therapeutics](#)

9:25am Wellness Break

Get-up and have a stretch before the next session begins.

9:30am Presentation: **Genetic Variations in SIRP α Impact CD47 Interactions.**

Michal Caspi Tal, Instructor & Team Lead, [Stanford University](#)

9:50am Wellness Break

Get-up and have a stretch before the next session begins.

Location: **Sessions**

9:55am Panel Discussion: **How Can we Manage Toxicity and Improve Clinical Practice?**

- What toxicities have been identified during preclinical & clinical trials?
- Are there specific causes for toxicity and how can we negate these?
- Are pre-clinical non-human samples posing problems for future clinical trials?
- How will the RACE for Children Act affect clinical trials?
- How else can we build best practices in clinic?

Tabitha Cooney, Physician, Neuro-Oncology, [Dana Farber Cancer Institute](#)

Michael Dougan, Assistant Professor, Medicine, [Harvard Medical School](#)

Daniel Masylar, VP of Clinical Development for Oncology, [Alector](#)

10:20am-10:40am **Open Q&A with Speakers**

This is your chance to pose your burning questions to the expert speakers from the previous panel.

Tabitha Cooney, Physician, Neuro-Oncology, [Dana Farber Cancer Institute](#)

Michael Dougan, Assistant Professor, Medicine, [Harvard Medical School](#)

Daniel Masylar, VP of Clinical Development for Oncology, [Alector](#)

10:40am Wellness Break

Get-up and have a stretch before the next session begins.

Location: **Stage**

10:45am Presentation: **CD40 Enhances Type I Interferon Responses Downstream of CD47 Blockade to Bridge Innate and Adaptive Immunity.**

Taylor Schreiber, CEO, [Shattuck Labs](#)

11:05am Wellness Break

Get-up and have a stretch before the next session begins.

11:10am Presentation: **AO-176, A Highly Differentiated Clinical Stage Anti-CD47 Antibody.**

- We learn how Arch Oncology is working to bridge innate and adaptive anti-tumor immunity through development of AO-176.
- An insight into the clinical trials for AO-176 and what's to come.

Dan Pereira, CSO, [Arch Oncology](#)

11:30am Wellness Break

Get-up and have a stretch before the next session begins.

11:35am Presentation: **An Insight Into Alector's Novel Approach to Drive Anti-Tumor Immunity.**

Andrew Picentic, Staff Scientist & Program Lead, **Alector**

11:55am Wellness Break

Get-up and have a stretch before the next session begins.

Location: **Sessions**

12:00pm Panel Discussion: **Reflection and Progression - Where are We and What's Next for CD47/SIRP α ?**

- What challenges have we faced and how can we overcome these?
- Where do we expect to see the most growth in the next year?
- Should enhancing mediated-macrophage phagocytosis be a focus going forward?
- How is the future work on emerging "don't eat me" signals going to benefit from our work with CD47/SIRP α ?
- What have been our biggest takeaways from the CD47/SIRPa 2020 Summit?

Timothy Zheng, Executive Director, Immune Modulation, **Boehringer Ingelheim**

Taylor Schreiber, CEO, **Shattuck Labs**

Sebastian Nijman, Founder & Managing Director, [Scenic Biotech](#)

12:25pm-12:45pm **Open Q&A with Speakers**

This is your chance to pose your burning questions to the expert speakers from the previous panel.

Actively or passively take part in this session.

Timothy Zheng, Executive Director, Immune Modulation, [Boehringer Ingelheim](#)

Taylor Schreiber, CEO, [Shattuck Labs](#)

Sebastian Nijman, Founder & Managing Director, [Scenic Biotech](#)

12:45pm Close of The CD47/SIRPa Summit

Roll straight into the rest of your Thursday with no flight to catch!